Can a patient with elevated parathyroid hormone, impaired renal function, normal serum calcium, and vitamin D insufficiency be treated with teriparatide (Forteo) for osteoporosis?

Can This Patient Take Forteo for Osteoporosis?

This patient should NOT receive Forteo (teriparatide) until the elevated PTH is fully evaluated and secondary hyperparathyroidism is excluded or corrected. The combination of elevated PTH (157 pg/mL), moderate CKD (eGFR 45), and vitamin D insufficiency (27 ng/mL) creates significant concerns for both efficacy and safety.

Primary Concerns

Elevated PTH Requires Investigation First

The PTH of 157 is substantially elevated and must be addressed before considering teriparatide. This elevation could represent:

• Secondary hyperparathyroidism from vitamin D insufficiency and CKD
• Normocalcemic primary hyperparathyroidism (despite normal calcium of 9 mg/dL) 1
• CKD-mineral bone disorder with altered skeletal PTH responsiveness 2

Critical point: Teriparatide works by mimicking PTH action. Administering it when endogenous PTH is already elevated (particularly >2-3x upper limit of normal) may worsen bone quality rather than improve it, especially in CKD where skeletal PTH responsiveness is unpredictable 2.

Renal Impairment Complications

With eGFR 45, this patient has CKD Stage 3a-3b. The FDA label explicitly states that teriparatide pharmacokinetics are significantly altered in severe renal impairment (CrCl <30 mL/min), with 73% increased AUC and 77% prolonged half-life 3. While this patient's eGFR is above that threshold, important considerations remain:

• CKD-associated osteoporosis is fundamentally different from postmenopausal osteoporosis, with overlapping metabolic bone diseases requiring individualized rather than algorithmic management 2
• The underlying metabolic bone disease in CKD may not respond predictably to teriparatide 3
• Risk of hypercalcemia is increased, particularly problematic in CKD 3

Hypercalcemia Risk

The FDA label warns that teriparatide should not be used in patients with elevated serum calcium 4, 3. While this patient's calcium is currently normal at 9 mg/dL, the combination of:

• Elevated PTH
• Impaired renal function
• Teriparatide's known effect of increasing serum calcium 3

Creates substantial risk for developing hypercalcemia during treatment. In postmenopausal women, 11% developed at least one calcium value above normal, and 3% required dose reduction 3.

Required Steps Before Considering Teriparatide

1. Optimize Vitamin D Status

The vitamin D level of 27 ng/mL is insufficient. Correct vitamin D deficiency first - target 25(OH)D >30 ng/mL, potentially higher in CKD 2. This alone may substantially reduce PTH 5.

2. Reassess PTH After Vitamin D Repletion

After achieving adequate vitamin D levels (typically 8-12 weeks of supplementation), remeasure:

• PTH
• Serum calcium (including ionized calcium if available)
• Serum phosphate
• 24-hour urinary calcium

If PTH remains elevated despite vitamin D repletion, further workup for primary hyperparathyroidism is mandatory 1, 5.

3. Consider Bone Turnover Assessment

In CKD with elevated PTH, bone biopsy may be needed to determine bone turnover status (high vs. low turnover) 2. Teriparatide is contraindicated in high bone turnover states and may be ineffective or harmful when PTH is already driving excessive bone remodeling.

Alternative Approach

If osteoporosis treatment cannot be delayed:

For this specific patient, bisphosphonates would be safer initial therapy 4. They:

• Are effective in CKD Stage 3 (though avoid in Stage 4-5)
• Do not require normal PTH levels
• Reduce fracture risk effectively
• Have established safety profiles in renal impairment

The Endocrine Society guideline supports bisphosphonates as first-line therapy for most patients with osteoporosis 4.

When Teriparatide Might Be Reconsidered

Teriparatide could potentially be considered ONLY if:

1. Vitamin D is optimized (>30 ng/mL)
2. PTH normalizes or decreases to near-normal range
3. Primary hyperparathyroidism is definitively excluded
4. Bone turnover markers or biopsy confirm low-turnover bone disease
5. Patient has failed or cannot tolerate bisphosphonates
6. Close monitoring (calcium every 1-2 months initially) is feasible

Even then, evidence in CKD is limited to case reports showing variable responses 6, 7.

Key Pitfalls to Avoid

• Do not assume elevated PTH is "just" secondary hyperparathyroidism without proper workup - normocalcemic primary hyperparathyroidism exists 1, 8
• Do not use teriparatide as first-line therapy when bisphosphonates are appropriate and safer 4
• Do not ignore the CKD context - bone disease in CKD requires specialized management distinct from typical osteoporosis 2
• Do not start teriparatide without correcting vitamin D deficiency first 5